India-based pharmaceutical company Lupin said Wednesday it has launched a drug that is bioequivalent to Supernus Pharmaceuticals' (SUPN) Trokendi XR in the US.
Lupin's Topiramate extended-release capsules were launched after the US Food and Drug Administration approved its Abbreviated New Drug Application, the company said.
The drug is approved for partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome seizures in patients aged at least 6 years, as well as for prevention of migraines in patients 12 years and older, Lupin said.
Price: 48.94, Change: +0.54, Percent Change: +1.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments